These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23413158)

  • 1. FDA advisers support rescheduling of hydrocodone products.
    Traynor K
    Am J Health Syst Pharm; 2013 Mar; 70(5):383-4. PubMed ID: 23413158
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA to propose hydrocodone reclassification.
    J Calif Dent Assoc; 2014 Jan; 42(1):10. PubMed ID: 25080676
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA committee: More restrictions needed on hydrocodone combination products.
    Kuehn BM
    JAMA; 2013 Mar; 309(9):862. PubMed ID: 23462764
    [No Abstract]   [Full Text] [Related]  

  • 4. DEA reschedules hydrocodone combination products as schedule II.
    J Mich Dent Assoc; 2014 Oct; 96(10):11. PubMed ID: 25647867
    [No Abstract]   [Full Text] [Related]  

  • 5. Rescheduling of combination hydrocodone products: problems for long-term care practitioners.
    Mattingly Ii TJ
    Consult Pharm; 2015 Jan; 30(1):13-9. PubMed ID: 25591027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Better late than never: time to up-schedule hydrocodone combination products.
    Kolodny A
    Pain Med; 2013 Nov; 14(11):1627-8. PubMed ID: 24238352
    [No Abstract]   [Full Text] [Related]  

  • 7. Physicians' intention to prescribe hydrocodone combination products after rescheduling: A theory of reasoned action approach.
    Fleming ML; Driver L; Sansgiry SS; Abughosh SM; Wanat M; Sawant RV; Ferries E; Reeve K; Todd KH
    Res Social Adm Pharm; 2017; 13(3):503-512. PubMed ID: 27567741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The downside of upscheduling.
    Gudin J; Lee AJ
    Pain Med; 2013 Nov; 14(11):1628-9. PubMed ID: 24238353
    [No Abstract]   [Full Text] [Related]  

  • 9. Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2014 Aug; 79(163):49661-82. PubMed ID: 25167591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments toward the safer use of opioids, with a focus on hydrocodone.
    Covvey JR
    Res Social Adm Pharm; 2015; 11(6):901-8. PubMed ID: 25769501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrocodone rescheduling.
    Wroten D
    J Ark Med Soc; 2014 Nov; 111(6):100. PubMed ID: 25654919
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA advisory panel assesses hydrocodone prescription writing: every dentist's responsibility.
    Curro FA
    J Am Dent Assoc; 2013 May; 144(5):462-4. PubMed ID: 23633687
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent issues regarding controlled substances.
    Helgeland D
    S D Med; 2013 Mar; 66(3):105, 107. PubMed ID: 23544298
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydrocodone prescriptions.
    Liewehr FR
    J Am Dent Assoc; 2013 Aug; 144(8):876. PubMed ID: 23904570
    [No Abstract]   [Full Text] [Related]  

  • 15. Rules set for dissemination of off-label-use information.
    Miller JL
    Am J Health Syst Pharm; 1999 Feb; 56(3):204. PubMed ID: 10030500
    [No Abstract]   [Full Text] [Related]  

  • 16. Upscheduling of hydrocodone: convenience and access vs patient safety measures.
    Schatman ME; Darnall BD
    Pain Med; 2013 Nov; 14(11):1627. PubMed ID: 24238351
    [No Abstract]   [Full Text] [Related]  

  • 17. DEA reschedules hydrocodone, makes changes to controlled substance disposal.
    Traynor K
    Am J Health Syst Pharm; 2014 Nov; 71(22):1916-8. PubMed ID: 25349231
    [No Abstract]   [Full Text] [Related]  

  • 18. An empty toolbox: hydrocodone to schedule II.
    Berger BJ
    Ann Emerg Med; 2014 Dec; 64(6):19A-21A. PubMed ID: 25606604
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context.
    Leiderman DB
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Déjà vu all over again!
    Allen LV
    Int J Pharm Compd; 2014; 18(3):180. PubMed ID: 25306763
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.